Objective:To study the differential expression of VEGF, SDF-1 and CXCR4 in colorectal cancer tissue and paracancerous tissues, and analyze the correlation between the three and the clinic pathological parameters of gastric cancer;to investigate the significance of the expression of VEGF,SDF-1 and CXCR4 in the progression of colorectal cancer.Methods:Immuno-histochemistry streptavidin-biotin complex( SABC) method and real-time Q-PCR were used to detect the operation resection of colorectal carcinoma and tumor-adjacent specimens of SDF-1,CXCR4 and VEGF expression.Results: On the mRNA level,compared with the adjacent tissues,the expression of SDF-1, CXCR4 and VEGF in colorectal cancer tissues was significant higher .The IHC′s results indicate that the positive rate of SDF-1,CXCR4 and VEGF in colorectal cancer were 78.7%,60% and 66.3%,the positive rate of adjacent tissues was 37.5%,42.5% and 28.8%, and there was statistically significant between expression and carcinoma adjacent tissue differences( P<0.05).There was statistically significant difference in the expression of SDF-1 with tumor metastasis,lymph node metastasis,TNM staging(P<0.05-P<0.01),while had no difference with gender,size and depth of invasion.There was statistically sig-nificant difference in the expression of CXCR4 with node metastasis,TNM in tumor staging ( P<0.05-P<0.01).It showed a significant negative correlation in SDF-1 expression and CXCR4,VEGF expression(P<0.01).Conclusion: It has a certain relationship between biological characteristics and SDF-1, CXCR4 and VEGF expression in colorectal cancer tissues.These results indicate that the expression of SDF-1,CXCR4 and VEGF play an important role in the tumorigenesis,progression,invasion and metastasis of colorectal cancer.

Objective To observe curative effect of lobaplatin plus etoposide,the new antitumor platinum drugs,on the untreated esophageal small cell of carcinoma.Methods Sixteen patients with esophageal small cell of carcinoma were treated using the lobaplatin/vp16 regimen.Results The complete response (CR) rates were 31.3%,partial response (PR)rates were 37.5%,stable disease (SD)rates were 25%,progressive disease (PD) rates were 6.25%,overall response rate (ORR)68.8%.Languor was the most common symptom in the grade -ⅠtoⅣ adverse reactions.All patients had symptoms of languor.Other related symptoms included the anaemia (41.7%), leukocytopenia (39.7%),thrombocytopenia (20.9%),anorexia,vomiting,nausea (29.3%)and increase of ALT and AST (14.5%).The toxic effect was not serious damage.Conclusion Lobaplatin is a new and safe antitumor platinum drug with a promising clinical effect,has a good tolerance in patients,and it can try to be used in the patients who have esophageal small cell of carcinoma.

Objective:To explore the effectiveness of the Exowalk gait training robot in improving the walking ability of stroke survivors.Methods:Forty stroke survivors were randomly divided into a control group and an experimental group, each of 20. In their rehabilitation, the control group was given routine walking training, while the experimental group′s training was assisted with the Exowalk robot. Both groups trained for 60 minutes a day, five days a week for four weeks. Before as well as after 2 and 4 weeks of training functional ambulatory categories (FACs), the Berg balance scale (BBS), the 6-minute walking test (6MWT), the 10-minute walking test (10MWT), the Rivermead mobility index and an exercise index were used to evaluate those in both groups.Results:After 2 weeks significant improvement was observed in the average FAC, BBS, 6MWT and 10MWT results of both groups, without significant differences between them. After 4 weeks there was still no significant difference in the groups′ average BBS scores. However, the average FAC rating in the experimental group had improved significantly while there was no significant increase in the control group′s average score.Conclusions:The Exowalk robot can help to improve the balance and walking ability of hemiplegic stroke survivors.

Objective:To provide epidemiological data and clinical evidence for cosmetic adverse reactions.Methods:A retrospective clinical analysis was carried out on a total 820 outpatients (23 males and 797 females) suspected to be with cosmetic adverse reactions from January 2014 - October 2017, and average age of these patients was 7~75 (32.66±8.09) years. Suspicious cosmetics patch tests were performed in some patients. Suspicious cosmetics patch tests were performed in 687 patients.Results:Among 820 patients with cosmetic adverse reactions, women accounted for 97.20% and men accounted for 2.80%. Age distribution was most common among young people aged 21-40 years, accounting for 71.34%. The highest level of education was higher education, accounting for 59.69%. Occupational distribution was most commonly concentrated in employees and unemployed persons, accounting for 28.54% and 18.66%, respectively. A history of cosmetics allergies accounted for 17.28%. Cosmetic contact dermatitis was the most common clinical type of cosmetic adverse reactions, accounting for 92.70%. A total of 1682 suspected pathogenic cosmetics were involved. The positive rate of the cosmetic original patch test was 42.39%. Among the cosmetics with a positive patch test, moisturizing, anti-wrinkle and whitening freckle cosmetics accounted for the highest proportion, 31.59%, 15.09%, and 12.68%, respectively.Conclusions:Cosmetic contact dermatitis is the most common type of cosmetic adverse reaction. Patch testing is helpful in identifying the contact allergens in cosmetic adverse reaction.